Anchored by Science
In the early days of his research, Dr Ali Fathi recognised the human body’s ability to function as the optimal bioreactor for tissue regeneration. Ali’s PhD at the University of Sydney, focused on the development of a smart biomaterial using the innate ability of the body to repair damaged tissue. Anchored by science, this was the genesis of Tetramatrix and the subsequent family of patents and publications that would follow. Ali was inspired by his entrepreneurial awareness of the impact that this translational science would have on patients around the world.
Focused and Agile
As a fellow chemical engineer at the University of Sydney, Terence Abrams was introduced to the technology and shared Ali’s enthusiasm for Tetramatrix. Armed with the experience and understanding of bespoke chemical manufacturing, Tez worked with Ali to incorporate the company Tetratherix and secure seed funding and crucial government grants. By 2017 they had established their own certified production facility in Sydney, followed shortly by the first clinical trial of the technology and successful IP assignment in 2019.
Geared for Growth
While leading the development and commercialization of innovations in regenerative medicine, Will Knox was introduced to Tetratherix in 2018. Will’s experience in managing global commercialization of medtech shaped a unique appreciation for the technology’s wide-reaching clinical benefit and exciting market potential. The founding team was completed by Will’s appointment as CEO which provides the commercial context to define and deliver the Tetratherix mission, vision and culture. Leading innovation in regenerative medicine and with a clear path to global expansion, we are geared for growth and excited about our future.
1
/
3